| 摘要 |
The present invention relates to methods for inhibiting stenosis, obstruction, or calcification of a valve following implantation of a valve prosthesis which may involve disposing a coating composition which is a combination of two different drugs one to target inflammation and attachment of the target cell and the second drug to inhibit proliferation and calcification on an elastical stent, gortex graft or valve leaflet, the combination effect of the two drug therapies incorporated into the polymer to attach to the bioprosthesis will improve the efficacy of the inhibition of calcification and the improvement of the longevity of the prosthetic material including the stent, the valve, and the gortex covering. The valve prosthesis and or gortex graft is mounted on the elastical stent or prosthesis such that the elastical stent is in contact with the valve. |
| 主权项 |
1. A method for inhibiting stenosis, obstruction, or calcification of a bioprosthetic valve following implantation of said bioprosthetic valve in a vessel having a wall, said method comprising:
providing a bioprosthetic valve for surgical replacement of a natural diseased valve, said bioprosthetic value including an elastical stent; providing a coating composition which is a combination of two agents on said elastical stent, bioprosthetic valve or both, wherein the coating composition comprises an effective amount of Atorvastatin at 80 mg dosing in combination with any one of the anti-restenotic agents for use with the stents, gortex grafts and bioprosthesis including: Anti-proliferative and anti-calcific agents including Sirolimus (and analog), Paclitaxel, Taxane, Dexamethasone, M-Prednisolone, Interferon gamma-1b, Leflunomide, Tacrolimus, Mycophenolic acid, Mizoribine, Cyclosproin, Tanilast, Biorest, Anti-proliferative Agents, Sirolmus (and analogs), Paclitaxol, Taxane, Actinomycin D, Methotrexate, Angiopeptin, Vincristine, Mitomycin, C Myc antisense, RestenASE, 2-Chloro-deoxyadenosine, PCNA ribozyme: Smooth Muscle Cell migration inhibitors, extracellular matrix modulators, Batimastat, Prolyl hydroxylase inhibitors, Halofuginone, C-proteinase inhibitors, Probucol, and a Mapkinase inhibitor MEK (5.0-10 ug/ml), (Drug dosing for current drugs on the stents that are on the US market Sirolimus 140 mcg/cm2, Paclitaxel dosing 1 mcg/mm2, Everolimus doing 100 mcg/cm2, Zotarolimus 10 mcg/1 mm stent length, Biolimus 15.6 mcg/mm2) and an effective dose of Atorvastatin 80 mg to improve the efficacy of the inhibition of calcification and the improvement of the longevity of the prosthetic material including the stent, the valve, and the gortex covering; implanting said bioprosthetic valve into said vessel by surgically removing a natural valve and replacing said natural valve with said bioprosthesis or placing said bioprosthesis over said natural valve having valve leaflets thereby compressing said natural valve leaflets against the vessel wall; eluting said therapeutic agents from said elastical stent, gortex graft, bioprosthetic valve or both; and causing the inhibition of stenosis, obstruction, or calcification of the bioprosthesis or the natural valve or both following implantation of the bioprosthetic valve. |
